BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy.

被引：0
|
作者：
Solca, F
Baum, A
Guth, B
Colbatzky, F
Blech, S
Amelsberg, A
Himmelsbach, F
机构：
[1] Boehringer Ingelheim Austria GmbH, Vienna, Austria
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：9025S / 9025S
页数：1
相关论文
共 50 条
  • [1] Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents
    Solca, F.
    Baum, A.
    Himmelsbach, F.
    Amelsberg, A.
    Adolf, G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 172 - 172
  • [2] BIBW-2992 Dual EGFR/HER2 Inhibitor Oncolytic
    Campas, C.
    Castaner, R.
    Bolos, J.
    DRUGS OF THE FUTURE, 2008, 33 (08) : 649 - 654
  • [3] BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations
    Yang Chih-Hsin
    Shih Jin-Yuan
    Su Wu-Chou
    Hsia Te-Chun
    Ho Ching-Liang
    Dudek, Arkadiusz Z.
    Terlizzi, Elizabeth
    Zhao Yihua M
    Shahidi, Mehdi
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S294 - S295
  • [4] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours.
    Shaw, H.
    Plummer, R.
    Vidal, L.
    Perrett, R.
    Pilkington, M.
    Temple, G.
    Fong, P.
    Amelsberg, A.
    Calvert, H.
    De Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 127S - 127S
  • [5] Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer
    Solca, F.
    Baum, A.
    Krause, M.
    Baumann, M.
    Wong, K. K.
    Greulich, H.
    Adolf, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 326 - 327
  • [6] A PHASE I STUDY OF DAILY BIBW 2992, AN IRREVERSIBLE EGFR/HER2 DUAL KINASE INHIBITOR, IN COMBINATION WITH WEEKLY PACLITAXEL
    Spicer, J. F.
    Harris, D.
    Ang, J.
    Chau, M.
    Vizor, S.
    Shahidi, M.
    Uttenreuther-Fischer, M.
    Southey, K.
    Chambers, J.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2008, 19 : 157 - 158
  • [7] Targeting EGFR/HER2 signaling pathway by a dual receptor tyrosine kinase inhibitor BIBW2992 for radiosensitization in murine urothelial carcinoma
    Yeh, Chih-Hsien
    Cheng, Jason Chia-Hsien
    Tsai, Yu-Chieh
    Tuan, Tsung Fan
    Ho, Pei-Yin
    Pu, Yeong-Shiau
    Cheng, Ann-Lii
    CANCER RESEARCH, 2012, 72
  • [8] A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor
    Plummer, R.
    Vida, L.
    Perrett, R.
    Spicer, J.
    Stopfer, P.
    Shahidi, M.
    Temple, G.
    Futreal, A.
    Calvert, H.
    de Bono, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 108 - 108
  • [9] Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations
    De Greve, J.
    Teugels, E.
    Geers, C.
    De Mey, J.
    in'tveld, P.
    Decoster, L.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Schallier, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 556
  • [10] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    Li, D.
    Ambrogio, L.
    Shimamura, T.
    Kubo, S.
    Takahashi, M.
    Chirieac, L. R.
    Padera, R. F.
    Shapiro, G. I.
    Baum, A.
    Himmelsbach, F.
    Rettig, W. J.
    Meyerson, M.
    Solca, F.
    Greulich, H.
    Wong, K-K
    ONCOGENE, 2008, 27 (34) : 4702 - 4711
12345